Agentschap NL   Report issue

Government Phase 1 Phase 3 Phase 4
Founded: Assen Netherlands (2010)

Organization Overview

First Clinical Trial
2010
NCT00752193
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Alternative names

Agentschap voor Innovatie door Wetenschap en Technologie

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arachnodactyly (Phase 3)

Asthma (Phase 4)

Cognition Disorders (Phase 1)

Dermatitis (Phase 3)

Dermatitis, Atopic (Phase 3)

Eczema (Phase 3)

Lung Diseases (Phase 3)

Lung Diseases, Obstructive (Phase 3)

Marfan Syndrome (Phase 3)

Pulmonary Disease, Chronic Obstructive (Phase 3)

Recurrence (Phase 3)

Schizophrenia (Phase 1)

Syndrome (Phase 3)

Urinary Bladder Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 9
  • # of Trial APIs: 11